12.4 ACZ885 (canakinumab), a new IL-1 beta blocking monoclonal antibody provides long-lasting remission in children with cryopyrin associated periodic syndrome (CAPS)

Ítems similars

• 12.4 ACZ885 (canakinumab), a new IL-1 beta blocking monoclonal antibody provides long-lasting remission in children with cryopyrin associated periodic syndrome (CAPS)
  per: Kümmerle-Deschner J, et al.
  Publicat: (2008-09-01)
• Canakinumab (ACZ885, a fully human IgG1 anti-IL-1β mAb) induces sustained remission in pediatric patients with cryopyrin-associated periodic syndrome (CAPS)
  per: Kuemmerle-Deschner, Jasmin B, et al.
  Publicat: (2011)
• The phagocyte specific protein S100A12 as a novel biomarker in Muckle-Wells-Syndrome before and during therapy with Anakinra and Canakinumab (ACZ885)
  per: Wittkowski, H, et al.
  Publicat: (2008)
• Canakinumab in patients with cryopyrin-associated periodic syndrome: an update for clinicians
  per: Kuemmerle-Deschner, Jasmin B., et al.
  Publicat: (2013)
• The interleukin 1 inhibitor canakinumab in the treatment of cryopyrin-associated periodic syndromes (CAPS): clinical experience
  per: Svetlana Olegovna Salugina, et al.
  Publicat: (2014-12-01)